15.76
-1.13%
Close of 9 Nov 2026, in MXN
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Genomma Lab Internacional SAB de CV
Its shares trade on BMV under the ticker LABB.MX. It has been listed since 19 June 2008. In the fiscal year to 31 December 2025, it reported revenue of MXN 17.54bn and net income of MXN 1.61bn. At that date it held total assets of MXN 23.83bn and shareholders' equity of MXN 11.11bn.
Genomma Lab Internacional SAB de CV engages in the development, manufacturing and marketing of pharmaceutical, beauty and personal care products. The company is headquartered in Mexico City, Mexico, D.F.. The company went IPO on 2008-06-19. The firm is engaged in the development, distribution and marketing of a range of products within different brands, for such treatments as anti-acne, varicose vein, hair loss, sexual stimulation and influenza; as well as analgesics and antifungals. The Company’s product portfolio includes such brands as Asepxia, Cicatricure, Goicoechea, Bengue, Diabet TX, Genoprazol, Goicotabs, Shot B, SilkaMedic, Siluet 40, Nikzon, X Ray, Next, Touch Me, Lomecan V and QG5, among others. The firm is a parent of a number of controlled entities, which have operations established in Mexico, the United States, Peru, Chile, Ecuador and Honduras, among others. In June 2014, the Company acquired 50% stake in Grupo Comercial e Industrial Marzam SA de CV.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 19 Jun 2008
- Employees
- 1,308
- Website
- genommalab.com/mx ↗
Leadership
Pay as last reported
- Mr. Rodrigo Alonso Herrera AspraExecutive Chairman of the Board of Directors, Founding Partner, since 2019
- Mr. Juan Marco SparvieriChief Executive Officer
- Mr. Jorge Luis Brake ValderramaVice Chairman of the Board, since 2018
- Mr. Antonio Zamora GallandExecutive Vice President, Chief Financial and Administrative Officer
- Mr. Alejandro Baston PatinoExecutive Vice President - Institutional Affairs, Media, Human Resources and Sustainability, since 2020
- Ms. Sabrina Lucila Herrera AspraExecutive Director, since 1998
- Mr. Efrain Tapia CordovaNon-Member Secretary of the Board of Directors
- Mr. Joaquin Ley PintoDirector
- Ms. Simona VisztovaDirector
- Mr. Juan AlonsoIndependent Director
- Mr. Marco Francisco Forastieri MunozIndependent Director
- Mr. Juan Carlos Gavito AspeIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 76
- Environment
- 98
- Social
- 99
- Governance
- 29
- Direct emissions (scope 1)
- 3,174.3 t
- Energy emissions (scope 2)
- 5,313.66 t
- Value chain emissions (scope 3)
- 44,075.12 t
- Women in the workforce
- 46.9%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Genomma Lab Internacional SAB de CV is a renowned company in the pharmaceutical industry, known for its strong market presence and brand recognition.
- The company has a diverse product portfolio consisting of various healthcare and personal care products, catering to different consumer needs.
- Genomma Lab has a competitive advantage in terms of its research and development capabilities, allowing them to innovate and introduce new products to the market.
- The company has a widespread distribution network, enabling them to reach a wide customer base effectively.
Weaknesses
- Genomma Lab has faced criticism regarding some of its marketing strategies, which have been deemed as exaggerations or misleading claims.
- The company may be vulnerable to regulatory changes in the healthcare industry, which could impact its product offerings and marketing strategies.
- Genomma Lab's reliance on external suppliers for raw materials and manufacturing processes may expose them to supply chain disruptions and quality control issues.
Opportunities
- The growing demand for healthcare and personal care products presents an opportunity for Genomma Lab to expand its market share and revenue.
- The emerging markets, especially in developing countries, offer untapped potential for Genomma Lab to introduce their products and gain new customers.
- Increasing consumer awareness and preference for natural and organic products open avenues for Genomma Lab to develop and market such offerings.
Threats
- The intense competition within the pharmaceutical industry poses a threat to Genomma Lab's market position and profitability.
- Economic fluctuations and recessions may impact consumer spending on non-essential healthcare and personal care products, affecting Genomma Lab's sales.
- Increasing prices of raw materials and production costs could potentially squeeze Genomma Lab's profit margins.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.